Leukeran, Chlorambucil Newswire

Leukeran, Chlorambucil Newswire

Comprehensive Real-Time News Feed for Leukeran, Chlorambucil (generic).

Results 1 - 20 of 27 in Leukeran, Chlorambucil (generic)

  1. Membranous nephropathy: a retrospective observational study of...Read the original story w/Photo

    Tuesday | BioMed Central

    Membranous nephropathy is the leading cause of nephrotic syndrome in adults. MN is a clinically heterogeneous disease and it is difficult to accurately predict outcomes at presentation and whom to treat with potentially toxic therapies.

    Comment?

  2. AbbVie Presents Results of - Studies on ImbruvicaRead the original story w/Photo

    Wednesday Jun 7 | GuruFocus.com

    Janssen Biotech Inc. showed a 44-month median period free survival before the disease started to progress again. The overall response rate of these patients to the treatment with Imbruvica was 91% while the rate of patients who completely responded to the treatment with AbbVie's Imbruvica was 9%.

    Comment?

  3. AbbVie Release: New Data Presented At ASCO 2017 Finds IMBRUVICA...Read the original story

    Sunday Jun 4 | BioSpace

    AbbVie Release: New Data Presented At ASCO 2017 Finds IMBRUVICA May Offer A More Targeted Approach To Chronic Lymphocytic Leukemia Treatment Than Chemotherapy Agent Chlorambucil In Treatment-NaA ve Patients /PRNewswire/ -- IMBRUVICA reduced cells that may play an important role in the survival and proliferation of chronic lymphocytic leukemia , without negatively impacting non-cancerous immune system cells, through one year of treatment, according to new data presented today at the 53rd Annual Meeting of the American Society of Clinical Oncology in ; abstract #7524 ).1 The data regarding IMBRUVICA, a first-in-class Bruton's tyrosine kinase inhibitor, were announced by AbbVie , a global biopharmaceutical company.

    Comment?

  4. TG Therapeutics Announces Successful Outcome From Pre-Planned Interim ...Read the original story

    Monday May 22 | BioSpace

    TG Therapeutics Announces Successful Outcome From Pre-Planned Interim Analysis By Independent DSMB In The UNITY-CLL Phase III Trial Contribution of single agents in the combination regimen successfully established pursuant to the UNITY-CLL Special Protocol Assessment; DSMB recommends no further enrollment to single agent arms DSMB reviewed updated safety data from more than 270 patients, finding no safety concerns and recommended continuation of enrollment without modification NEW YORK, May 23, 2017 -- TG Therapeutics, Inc. , today announced that the independent Data Safety Monitoring Board of the UNITY-CLL Phase 3 trial has successfully completed a pre-specified interim analysis to assess the contribution of TG-1101 and TGR-1202 in the combination regimen of TG-1101 plus TGR-1202.

    Comment?

  5. TG Therapeutics' combo regimen deemed safe in late-stage CLL study; shares ahead 9% premarketRead the original story w/Photo

    Tuesday May 23 | Seeking Alpha

    TG Therapeutics is up 9% premarket on average volume in response to its announcement that an interim analysis of its Phase 3 clinical trial assessing the combination of TG-1101 and TGR-1202 and each candidate alone in patients with chronic lymphocytic leukemia . The analysis, conducted by the independent Data Safety Monitoring Board, showed the contribution of the combination has been established and is safe so recruitment in the single agent arms will cease.

    Comment?

  6. TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned...Read the original story

    Tuesday May 23 | Customer Interaction Solutions

    TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial Contribution of single agents in the combination regimen successfully established pursuant to the UNITY-CLL Special Protocol Assessment; DSMB recommends no further enrollment to single agent arms DSMB reviewed updated safety data from more than 270 patients, finding no safety concerns and recommended continuation of enrollment without modification NEW YORK, May 23, 2017 -- TG Therapeutics, Inc. , today announced that the independent Data Safety Monitoring Board of the UNITY-CLL Phase 3 trial has successfully completed a pre-specified interim analysis to assess the contribution of TG-1101 and TGR-1202 in the combination regimen of TG-1101 plus TGR-1202.

    Comment?

  7. Single Agent Chemotherapy Market Research Report: Market Competition, ...Read the original story w/Photo

    May 18, 2017 | SBWire

    Single agent chemotherapy refers to the treatment of cancer with a potent single chemotherapy drug instead of multiple chemotherapy agents. Though, the combination chemotherapy is standard treatment method in most of cancer cases, increasing burden of high risk side effects and adverse effects of combination therapy has promoted use of single agent in management of cancer.

    Comment?

  8. AbbVie: 23 abstracts to be presented at ASCORead the original story w/Photo

    May 18, 2017 | Seeking Alpha

    AbbVie announces that 23 abstracts across a range of tumor types have been accepted for presentation at ASCO. Highlights : Ibutinib: long-term follow-up data from RESONATE : Monday, June 5 in the am; versus chlorambucil in CLL: Monday, June 5 in the am; Phase 3 data in GvHD: Monday, June 5 in the am; Phase 3 data with rituximab: Monday, June 5 in the am.

    Comment?

  9. Aspen Faces EU Antitrust Probe Over Pricing of Cancer DrugsRead the original story

    May 15, 2017 | The Washington Post

    Aspen Pharmacare Holdings Ltd. faces a European Union antitrust probe for ramping up the price of cancer drugs as the EU joins a global crackdown on the soaring cost of life-saving generic medicines. "When the price of a drug suddenly goes up by several hundred percent, this is something the commission may look at," EU Competition Commissioner Margrethe Vestager said in an emailed statement on Monday.

    Comment?

  10. EU launches probe into Aspen Pharma cancer drug pricingRead the original story w/Photo

    May 15, 2017 | Live Charts

    European regulators have launched a formal investigation into Aspen Pharma over concerns that the South Africa company's prices for life-saving cancer medicines are "excessive". The European Commission will investigate whether Aspen has abused a dominant market position in breach of EU antitrust rules.

    Comment?

  11. AbbVie Release: IMBRUVICA (Ibrutinib) Pooled Outcomes Data From Three ...Read the original story

    May 14, 2017 | BioSpace

    AbbVie Release: IMBRUVICA Pooled Outcomes Data From Three Phase III Studies Suggest Potential Clinical Efficacy In Patients With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - Results from data presented at the International Workshop on Chronic Lymphocytic Leukemia further suggest that risk factors typically associated with poor clinical outcomes may be less relevant with ibrutinib treatment - In ibrutinib-treated patients, the presence of deletion 11q was associated with trends of longer progression free survival at 24 months and overall survival at 30 months /PRNewswire/ -- AbbVie , a global biopharmaceutical company, today announced results from an analysis of data pooled from three Phase 3 studies evaluating IMBRUVICA use in patients with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma : RESONATETM , RESONATETM-2 and HELIOS .

    Comment?

  12. Big Pharma conspired to destroy supply of life-saving cancer drugs by putting profit before peopleRead the original story w/Photo

    Apr 23, 2017 | NewsTarget.com

    If you are familiar with the fraudulent practices of the pharmaceutical industry, then you know how much power some of these companies have. Cancer drugs are a multi-billion dollar business.

    Comment?

  13. DA wants probe into Aspen anti-competitive allegationsRead the original story w/Photo

    Apr 19, 2017 | Iol.co.za

    The Democratic Alliance said on Wednesday it would write to the Competition Commission and the Medicines Control Council to request that they investigate the market conduct of Aspen Pharmacare, the leading South African pharmaceutical company. This comes after reports in the United Kingdom and South Africa detailing how staff at Aspen Pharmacare allegedly plotted to dispose of life-saving cancer medication in order to drive up its price across Europe.

    Comment?

  14. Drug firm plots to 'destroy life-saving cancer drugs in bid to drive up prices'Read the original story w/Photo

    Apr 14, 2017 | Mirror.co.uk

    A drug firm plotted to destroy supplies of life-saving cancer medicines over a battle to drive up prices, it has been claimed. South African firm Aspen Pharmacare is understood to have proposed the wastage during a row with the Spanish health service in 2014.

    Comment?

  15. Drug giant 'plotted to destroy stocks of cancer medicines'Read the original story w/Photo

    Apr 14, 2017 | Daily Mail

    Firm increased price of leukaemia drug busulfan in England and Wales from A 5.20 to A 65.22 per packet, a rise of 1,100 per cent One of the world's leading drug companies 'plotted to destroy supplies of life-saving cancer medicines' over a battle to drive up prices in Europe, it has been claimed. South African firm Aspen Pharmacare is understood to have proposed the wastage during a row with the Spanish health service in 2014, while it is also said to have threatened to stop supplying medicine to Italian authorities a year earlier.

    Comment?

  16. Chronic lymphocytic leukemia skin infiltration mimicking an ICD pocket infection: a case reportRead the original story w/Photo

    Mar 23, 2017 | BioMed Central

    We are presenting a case report on an unreported and unusual cutaneous manifestation of chronic lymphocytic leukemia in a patient with an implantable cardioverter-defibrillator . A 65-year-old man with a history of chronic lymphocytic leukemia , previously treated with chlorambucil, was referred in October 2013 for extraction of a single chamber ICD due to a suspected device-related infection in the pulse generator area .

    Comment?

  17. Characterizing and prognosticating chronic lymphocytic leukemia in...Read the original story w/Photo

    Mar 15, 2017 | BioMed Central

    The ConnectA CLL registry is a multicenter, prospective observational cohort study, which enrolled 1494 adult patients between 2010-2014, at 199 US sites. Patients with CLL were enrolled within 2 months of initiating first line of therapy or a subsequent LOT showed that the improvement in overall survival noted in younger patients was less pronounced in the elderly [ Whether these differences are related to disparities in therapeutic choice, access to care, non-CLL-related deaths in elderly patients, or variations in CLL biology and prognostic indicators is unknown.

    Comment?

  18. Randomized phase 3 study of lenalidomide versus chlorambucil as...Read the original story

    Feb 17, 2017 | Leukemia

    Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia Lenalidomide Revlimid; Celgene Corporation, Summit, NJ, USA), an oral immunomodulatory agent, demonstrated activity in phase 2 trials in patients with chronic lymphocytic leukemia in front-line therapy 4 An open-label, randomized, multicenter, phase 3, parallel-group study was conducted evaluating LEN as first-line therapy for elderly patients with CLL ). Chlorambucil , a standard front-line therapy for elderly patients at trial initiation, was used as a comparator.

    Comment?

  19. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patientsRead the original story w/Photo

    Jan 4, 2017 | BioMed Central

    The KDIGO Clinical Practice Guidelines for Glomerulonephritis recommended tacrolimus as an alternative regimen for the initial therapy for Idiopathic membranous nephropathy , however, large observational studies evaluating tacrolimus treatment in IMN remains rare. A total of 408 consecutive IMN patients with nephrotic syndrome who were treated with tacrolimus in Jinling Hospital were included.

    Comment?

  20. Management of Membranous Nephropathy in Asia.Read the original story

    Dec 14, 2016 | CiteULike

    Membranous nephropathy is the most common cause of nephrotic syndrome in adults, accounting for about 20.0% of all NS cases. With an increasing prevalence, especially in the elderly, it has received great attention in Asia.

    Comment?